From the Imaging Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Clin Nucl Med. 2017 Jun;42(6):e313-e316. doi: 10.1097/RLU.0000000000001620.
PET-CT with somatostatin analogs labeled with Ga is increasingly recognized as the best imaging modality for the evaluation of well-differentiated neuroendocrine tumors (NETs). However, somatostatin receptor (SSR) is not an exclusive marker for NET. A variety of tumors other than NETs express SSR, leading to a significant risk of false-positive PET/CT results. We illustrate false-positive Ga-DOTATATE PET/CT findings due to high uptake by non-Hodgkin lymphoma, metastatic meningioma, breast cancer, thyroid adenoma, and papillary carcinoma. Although Ga-DOTATATE is a noteworthy tracer for oncological application, pathological conditions with overexpression of SSR should be recognized to prevent misinterpretation of PET/CT images.
正电子发射断层扫描（PET）-CT 联合生长抑素类似物标记的镓（Ga）越来越被认为是评估分化良好的神经内分泌肿瘤（NET）的最佳影像学方法。然而，生长抑素受体（SSR）并不是 NET 的唯一标志物。除 NET 以外的多种肿瘤也表达 SSR，导致 PET/CT 结果出现假阳性的风险显著增加。我们展示了由于非霍奇金淋巴瘤、转移性脑膜瘤、乳腺癌、甲状腺腺瘤和甲状腺乳头状癌摄取 Ga-DOTATATE 而导致的假阳性 Ga-DOTATATE PET/CT 结果。虽然 Ga-DOTATATE 是一种有意义的用于肿瘤学应用的示踪剂，但应认识到 SSR 过度表达的病理情况，以防止对 PET/CT 图像的错误解读。
